INGIX | VFFSX | INGIX / VFFSX | |
Total Expense Ratio | N/A | N/A | - |
Annual Report Gross Expense Ratio | N/A | N/A | - |
Fund Existence | 21 years | 9 years | - |
Gain YTD | 3.503 | 3.541 | 99% |
Front Load | N/A | N/A | - |
Min. Initial Investment | 0 | 5000000000 | - |
Min. Initial Investment IRA | N/A | N/A | - |
Net Assets | 4.14B | 1.35T | 0% |
Annual Yield % from dividends | 1.22 | 1.33 | 92% |
Returns for 1 year | 16.93 | 25.24 | 67% |
Returns for 3 years | 8.26 | 38.58 | 21% |
Returns for 5 years | 29.66 | 84.90 | 35% |
Returns for 10 years | 67.89 | N/A | - |
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
QCLGX | 25.91 | 0.37 | +1.45% |
Federated Hermes MDT Large Cap Growth C | |||
FCICX | 16.75 | 0.14 | +0.84% |
NYLI PineStone International Equity Cl C | |||
PRHSX | 83.04 | 0.31 | +0.37% |
T. Rowe Price Health Sciences | |||
NMUCX | 9.78 | 0.01 | +0.10% |
Neuberger Berman Multi-Cap Opp C | |||
SEQPX | 16.48 | -0.01 | -0.06% |
NAA World Equity Income P |